212 related articles for article (PubMed ID: 37006537)
21. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Liu G; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
[TBL] [Abstract][Full Text] [Related]
22. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
23. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.
Zheng Z; Fang L; Cai H
BMJ Open; 2023 Dec; 13(12):e076383. PubMed ID: 38101853
[TBL] [Abstract][Full Text] [Related]
25. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
26. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
Wang Y; Rui M; Yang L; Wang X; Shang Y; Ma A; Li H
Front Public Health; 2021; 9():650392. PubMed ID: 33889559
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial.
Zhu Y; Liu K; Zhu H; Cao H; Zhou Y
Ther Adv Med Oncol; 2023; 15():17588359231206147. PubMed ID: 37846397
[TBL] [Abstract][Full Text] [Related]
29. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.
Su Y; Fu J; Du J; Wu B
Ther Adv Med Oncol; 2020; 12():1758835920950199. PubMed ID: 32874210
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T; Li Y; Zheng X
BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
[TBL] [Abstract][Full Text] [Related]
33. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
34. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
35. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
[TBL] [Abstract][Full Text] [Related]
36. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
Han J; Zeng N; Tian K; Liu Z; She L; Wang Z; He J; Chen N
Head Neck; 2023 Sep; 45(9):2246-2258. PubMed ID: 37435624
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
[TBL] [Abstract][Full Text] [Related]
39. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
40. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
